Connect
← Return to Starting Bendamustine and Rituxin for Follicular Lymphoma
Discussion
Starting Bendamustine and Rituxin for Follicular Lymphoma
Blood Cancers & Disorders | Last Active: Apr 24 6:52am | Replies (14)Comment receiving replies
Wanting to know information concerning treatment with Brukinsa(zanabrutinib) versus Bendamustine and Rituxan for CLL What are the advantages or side effects in comparison ?
I believe Brukinsa has just been approved by the FDA.
Replies to "Wanting to know information concerning treatment with Brukinsa(zanabrutinib) versus Bendamustine and Rituxan for CLL What are..."
Connect
@jam5, you are watching new treatment developments for CLL very closely. 🙂 You're right that zanubrutinib (Brukinsa) was approved for use in patients with CLL and SLL just a few days ago (Jan. 19, 2023).
- FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
Here's a study comparing zanubrutinib versus bendamustine and rituximab that shows promise:
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial | Lancet Oncology 2022 https://pubmed.ncbi.nlm.nih.gov/35810754/
EXCERPT:
"Interpretation: Zanubrutinib significantly improved progression-free survival versus bendamustine-rituximab, with an acceptable safety profile consistent with previous studies. These data support zanubrutinib as a potential new treatment option for untreated CLL and SLL."